At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, ...
The FDA approved a new safety warning for Depo-Provera alerting patients to a possible risk for a type of brain tumor called meningioma.
The MarketWatch News Department was not involved in the creation of this content. The number of lawsuits filed has tripled to over 1300 since May New US peer-reviewed study adds to body of research ...
Depot medroxyprogesterone acetate (DMPA) can prevent pregnancy for up to three months, and is available in a form that can be ...
Recent studies how found evidence that Depo-Provera massively increases the risk of developing brain tumors even after women ...
MARLTON, N.J., March 12, 2025 /PRNewswire/ -- A growing number of women who received Depo-Provera injections are coming forward with serious health concerns following new research linking the ...
Nov. 22, 2004 — The U.S. Food and Drug Administration (FDA) and Pfizer have notified healthcare professionals via letter of revisions to the safety labeling for medroxyprogesterone acetate (MPA) ...
Risk factors for repeat pregnancy terminations include teenage pregnancy, social deprivation, two or more previous live births or miscarriages at the time of the initial termination, and the use of ...
The decision comes as Pfizer faces lawsuits from more than 1000 women who say the company knew about the risks and didn’t warn them. The agency signed off last week on a label update for 2 versions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback